Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

91 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The crosstalk between lung cancer and the bone marrow niche fuels emergency myelopoiesis.
Calderon-Espinosa E, De Ridder K, Benoot T, Jansen Y, Vanhonacker D, Heestermans R, De Becker A, Van Riet I, Decoster L, Goyvaerts C. Calderon-Espinosa E, et al. Among authors: jansen y. Front Immunol. 2024 Aug 1;15:1397469. doi: 10.3389/fimmu.2024.1397469. eCollection 2024. Front Immunol. 2024. PMID: 39148724 Free PMC article. Review.
A randomized controlled phase II clinical trial on mRNA electroporated autologous monocyte-derived dendritic cells (TriMixDC-MEL) as adjuvant treatment for stage III/IV melanoma patients who are disease-free following the resection of macrometastases.
Jansen Y, Kruse V, Corthals J, Schats K, van Dam PJ, Seremet T, Heirman C, Brochez L, Kockx M, Thielemans K, Neyns B. Jansen Y, et al. Cancer Immunol Immunother. 2020 Dec;69(12):2589-2598. doi: 10.1007/s00262-020-02618-4. Epub 2020 Jun 26. Cancer Immunol Immunother. 2020. PMID: 32591862 Free PMC article. Clinical Trial.
Molecular and epigenetic features of melanomas and tumor immune microenvironment linked to durable remission to ipilimumab-based immunotherapy in metastatic patients.
Seremet T, Koch A, Jansen Y, Schreuer M, Wilgenhof S, Del Marmol V, Liènard D, Thielemans K, Schats K, Kockx M, Van Criekinge W, Coulie PG, De Meyer T, van Baren N, Neyns B. Seremet T, et al. Among authors: jansen y. J Transl Med. 2016 Aug 2;14(1):232. doi: 10.1186/s12967-016-0990-x. J Transl Med. 2016. PMID: 27484791 Free PMC article.
Illustrative cases for monitoring by quantitative analysis of BRAF/NRAS ctDNA mutations in liquid biopsies of metastatic melanoma patients who gained clinical benefits from anti-PD1 antibody therapy.
Seremet T, Planken S, Schreuer M, Jansen Y, Delaunoy M, El Housni H, Lienard D, Del Marmol V, Heimann P, Neyns B. Seremet T, et al. Among authors: jansen y. Melanoma Res. 2018 Feb;28(1):65-70. doi: 10.1097/CMR.0000000000000415. Melanoma Res. 2018. PMID: 29227333
Undetectable circulating tumor DNA (ctDNA) levels correlate with favorable outcome in metastatic melanoma patients treated with anti-PD1 therapy.
Seremet T, Jansen Y, Planken S, Njimi H, Delaunoy M, El Housni H, Awada G, Schwarze JK, Keyaerts M, Everaert H, Lienard D, Del Marmol V, Heimann P, Neyns B. Seremet T, et al. Among authors: jansen y. J Transl Med. 2019 Sep 5;17(1):303. doi: 10.1186/s12967-019-2051-8. J Transl Med. 2019. PMID: 31488153 Free PMC article.
Quantitative assessment of BRAF V600 mutant circulating cell-free tumor DNA as a tool for therapeutic monitoring in metastatic melanoma patients treated with BRAF/MEK inhibitors.
Schreuer M, Meersseman G, Van Den Herrewegen S, Jansen Y, Chevolet I, Bott A, Wilgenhof S, Seremet T, Jacobs B, Buyl R, Maertens G, Neyns B. Schreuer M, et al. Among authors: jansen y. J Transl Med. 2016 Apr 19;14:95. doi: 10.1186/s12967-016-0852-6. J Transl Med. 2016. PMID: 27095081 Free PMC article.
91 results